X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DISHMAN PHARMA VENUS REMEDIES/
DISHMAN PHARMA
 
P/E (TTM) x -4.1 25.1 - View Chart
P/BV x 0.2 3.3 4.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   DISHMAN PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
DISHMAN PHARMA
Mar-16
VENUS REMEDIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs126374 33.6%   
Low Rs61129 47.4%   
Sales per share (Unadj.) Rs301.8197.8 152.6%  
Earnings per share (Unadj.) Rs-24.921.2 -117.3%  
Cash flow per share (Unadj.) Rs2.534.7 7.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs293.3179.9 163.0%  
Shares outstanding (eoy) m12.3480.69 15.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 24.4%   
Avg P/E ratio x-3.811.9 -31.7%  
P/CF ratio (eoy) x36.77.2 507.0%  
Price / Book Value ratio x0.31.4 22.8%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m1,15420,306 5.7%   
No. of employees `0000.90.8 111.6%   
Total wages/salary Rs m3935,355 7.3%   
Avg. sales/employee Rs Th4,026.119,252.7 20.9%   
Avg. wages/employee Rs Th425.06,459.5 6.6%   
Avg. net profit/employee Rs Th-331.82,064.1 -16.1%   
INCOME DATA
Net Sales Rs m3,72415,961 23.3%  
Other income Rs m23265 8.5%   
Total revenues Rs m3,74716,226 23.1%   
Gross profit Rs m3954,103 9.6%  
Depreciation Rs m3381,091 31.0%   
Interest Rs m354944 37.5%   
Profit before tax Rs m-2752,334 -11.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32624 5.1%   
Profit after tax Rs m-3071,711 -17.9%  
Gross profit margin %10.625.7 41.2%  
Effective tax rate %-11.526.7 -43.0%   
Net profit margin %-8.210.7 -76.9%  
BALANCE SHEET DATA
Current assets Rs m2,63811,018 23.9%   
Current liabilities Rs m2,3059,517 24.2%   
Net working cap to sales %8.99.4 95.1%  
Current ratio x1.11.2 98.9%  
Inventory Days Days135110 122.6%  
Debtors Days Days4635 133.0%  
Net fixed assets Rs m4,87116,304 29.9%   
Share capital Rs m123161 76.5%   
"Free" reserves Rs m3,49612,907 27.1%   
Net worth Rs m3,61914,516 24.9%   
Long term debt Rs m1,3744,189 32.8%   
Total assets Rs m7,50929,805 25.2%  
Interest coverage x0.23.5 6.4%   
Debt to equity ratio x0.40.3 131.6%  
Sales to assets ratio x0.50.5 92.6%   
Return on assets %0.68.9 7.1%  
Return on equity %-8.511.8 -71.9%  
Return on capital %1.617.5 9.0%  
Exports to sales %024.8 0.0%   
Imports to sales %13.93.7 371.2%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs m517596 86.6%   
Fx inflow Rs m04,952 0.0%   
Fx outflow Rs m517697 74.1%   
Net fx Rs m-5174,255 -12.1%   
CASH FLOW
From Operations Rs m5142,786 18.5%  
From Investments Rs m-123-1,529 8.1%  
From Financial Activity Rs m-387-941 41.1%  
Net Cashflow Rs m4316 1.3%  

Share Holding

Indian Promoters % 32.9 61.4 53.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.7 4.9%  
FIIs % 0.6 12.7 4.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 22.1 300.5%  
Shareholders   20,121 46,261 43.5%  
Pledged promoter(s) holding % 36.4 35.8 101.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PANACEA BIOTECH  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note; Banking and Healthcare Stocks Witness Buying Interest(Closing)

Indian share markets ended their session on a positive note today. Gains were largely seen in the banking sector and healthcare sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 25, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ALEMBIC LTD COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS